Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 103

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 103
---
. GAAP, still existed as of December 31, 2021. We cannot assure you that we will not identify additional material weaknesses
or significant deficiencies in the future.

Our management concluded that
our internal controls over financial reporting were not effective as of December 31, 2021. Investors may lose confidence in our operating
results, the price of the Aptorum Class A ordinary shares could decline and we may be subject to litigation or regulatory enforcement
actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, the Aptorum Class A
ordinary shares may not be able to remain listed on the Nasdaq Capital Market.

<div align='center'>54</div>

We may market our products, if approved, globally; if we do, we will be subject to the risk of doing business internationally.

We operate and expect to operate
in various countries, and we may not be able to market our products in, or develop new products successfully for, these markets. We may
also encounter other risks of doing business internationally including but not limited to:

| ● | unexpected changes in, or impositions of, legislative or regulatory 
 requirements;                                                       |

| ● | efforts to develop an international sales, marketing and distribution                                                            
 organization may increase our expenses, divert our management’s attention from the acquisition or development of drug candidates 
 or cause us to forgo profitable licensing opportunities in these geographies;                                                    |

| ● | the occurrence of economic weakness, including inflation or 
 political instability;                                      |

| ● | the effects of applicable non-U.S. tax structures and potentially 
 adverse tax consequences;                                         |

| ● | differences in protection of our IP rights including patent 
 rights of other parties;                                    |

| ● | the burden of complying with a variety of foreign laws including 
 difficulties in effective enforcement of contractual provisions; |

| ● | delays resulting from difficulty in obtaining export licenses,                                                                       
 tariffs and other barriers and restrictions, potentially longer payment cycles, greater difficulty in accounts receivable collection 
 and potentially adverse tax treatment; and                                                                                           |

| ● | production shortages resulting from any events affecting raw 
 material supply or manufacturing capabilities abroad.        |

In addition, we are subject
to general geopolitical risks in foreign countries where we operate, such as political and economic instability and changes in diplomatic
and trade relationships, which could affect, among other things, customers’ inventory levels and consumer purchasing, which could
cause our results to fluctuate and our net sales to decline